MPM BioImpact’s Allogene Therapeutics ALLO Stock Holding History

MPM BioImpact’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,242,933	Closed	-$5.47M	–	39
2026 Q1	$5.47M	Buy	+2,242,933	New	+$4.5M	0.42%	39

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

MPM BioImpact's ALLO Position: Q2 2026 in Review

MPM BioImpact sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 2,242,933 shares — an estimated $5.47M sold.

MPM BioImpact first reported a position in ALLO in Q1 2026 and held it in 1 quarter. The position peaked at $5.47M in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

MPM BioImpact reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
MPM BioImpact sold 2,242,933 Allogene Therapeutics shares in Q2 2026, an estimated $5.47M.
MPM BioImpact first reported a position in Allogene Therapeutics in Q1 2026 and held it in 1 quarter.
MPM BioImpact's Allogene Therapeutics position peaked at $5.47M in Q1 2026.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.